Skip to search formSkip to main contentSkip to account menu

bortezomib 3.5 MG Injection [Velcade]

Known as: VELCADE 3.5 MG Injection, bortezomib 3.5 mg INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [VELCADE], bortezomib 3.5 mg SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [VELCADE] 
National Institutes of Health

Related topics

Related topics

4 relations
InjectionMannitolVelcadebortezomib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
5 (PSMB5) gene mutation and overexpression of PSMB5 protein β Molecular basis of bortezomib/Velcade® resistance: proteasome subunit
Review
2011
Review
2011
Apoptosis signaling in leukemia and lymphoma: understanding mechanisms of chemoresistance
Apoptosis (programmed cell death) is a basic physiological process, essential in the balance between life and death of cells of… 
2009
2009
Supériorité de l’association velcade dexaméthasone dans le traitement d’induction du myélome multiple avant autogreffe de cellules souches chez les patients de moins de 65 ans. Résultats du protocole…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)